Consensus

DOI: 10.4244/EIJ-JAA-202501

Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society

Jean-Claude Deharo1,2; Julien Dreyfus3; Maria-Grazia Bongiorni4; Haran Burri5; Pascal Defaye6; Michael Glikson7; Nigel Lever8; Antonio Mangieri9; Blandine Mondésert10; Jens Cosedis Nielsen11,12; Maully Shah13; Christoph Thomas Starck14; Archana Rao15; Christophe Leclercq16; Fabien Praz17; Sergio Richter18; Nicolas Amabile19, MD, PhD; Alexander Breitenstein20; Óscar Cano21,22, MD, PhD; Karol Čurila23; Jamie Manlucu24; Robert D. Schaller25; Hung-Fat Tse26; Christian Veltmann27; Zachary Whinnett28

Abstract

Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI. Graphical abstract.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 22
Nov 14, 2025
Volume 21 Number 22
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00046 Nov 14, 2025
HALT – an evolving understanding of the mechanisms of formation and clinical relevance
Leipsic J and Khoo J
free

Editorial

10.4244/EIJ-E-25-00041 Nov 14, 2025
Transcatheter aortic valve alignment: substantial progress, remaining gaps
Amat-Santos I and Pensotti F
free

Viewpoint

10.4244/EIJ-D-25-00692 Nov 14, 2025
Discontinuation of the ACURATE transcatheter heart valve platform: loss or reckoning?
Kim W and Möllmann H
free

State-of-the-Art

10.4244/EIJ-D-24-01069 Nov 14, 2025
Transcatheter treatment of bicuspid aortic valve stenosis
Tchétché D et al
free

Original Research

10.4244/EIJ-D-25-00682 Nov 14, 2025
Long-term outcomes and durability of balloon-expandable TAVI in small and large annuli
Yamamoto M et al

Original Research

10.4244/EIJ-D-25-00423 Nov 14, 2025
TRICURE: first-in-human study of the Topaz transcatheter tricuspid heart valve system
Teiger E et al

Letter to the editor

10.4244/EIJ-D-25-00842 Nov 14, 2025
Letter: Transcatheter aortic valve implantation and covert brain injury: does silence equal reassurance?
Pyrpyris N et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved